Trial Profile
A Multicenter, Open-label, Phase III Study to Determine the Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects Referred for Contrast-enhanced MRI of the Central Nervous System (CNS)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Jan 2022
Price :
$35
*
At a glance
- Drugs Gadobutrol (Primary)
- Indications Cerebrovascular disorders; Vascular disorders
- Focus Diagnostic use; Registrational
- Sponsors Bayer
- 26 Mar 2015 According to Bayer Healthcare media release, gadobutrol injection [Gadovis] has received regulatory approval in Japan for contrast-enhancement MRI in cranial, spinal, the body and extremeties at a dose of 0.1 mL/kg body weight.
- 11 May 2014 New trial record
- 30 Sep 2013